Pure Global AI
NCT06331598Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

A Phase II, Open Label, Randomized, Non-Comparative Cohorts Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
Hoffmann-La RochePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
Atezolizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hoffmann-La Roche
Location
Barcelona,Madrid,Sevilla, Spain
Timeline & enrollment
Phase
Phase 2
Start date
Jul 30, 2024
End date
Sep 20, 2029
Enrollment
40 participants
Primary outcome

Disease Free Survival (DFS) Rate at 24 Months

Summary

This study is being conducted to evaluate efficacy parameters (disease free survival [DFS]
 and overall survival [OS]) of atezolizumab and atezolizumab in combination with tiragolumab
 in TMB-H or MSI-H as adjuvant treatment after standard radical intended treatment in
 participants with intermediate-high risk of recurrence.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06331598
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06331598 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.